Glp-1 Analogues Market Size, Share, By Product (Ozempic, Trulicity, Mounjaro, Xultophy, Victoza, Saxenda, and Others), By Drug Class (Semaglutide, Dulaglutide, Liraglutide, and Exenatide), By Route of Administration (Parenteral, and Oral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region - Trends, Analysis and Forecast till 2034

Glp-1 Analogues Market Size was valued at USD 45.3 Billion in 2024 and is expected to reach USD 606.3 Billion by 2034, growing at a CAGR of 33%

GLP-1 analogs, also known as GLP-1 receptor agonists, are a class of medications used primarily to treat type 2 diabetes and, more recently, to manage weight. According to some experts, these medications function by replacing the activity of glucagon-like peptide-1, a naturally occurring hormone in the human body that regulates blood glucose and hunger. GLP-1 analogs enhanced the pancreas' insulin secretion in response to high blood glucose levels, resulting in delayed stomach emptying and reduced hunger via a direct effect on brain areas regulating hunger and fullness. The recent interest in GLP-1 analogs stems from their efficacy in treating diabetes and obesity. Active research is being conducted on their usage in neurological illnesses such as Alzheimer's, non-alcoholic fatty liver disease, and even some types of cancer. Third, as we learn more about these drugs, their role in medical treatment may shift, potentially opening up new therapeutic choices for a wide range of health issues.